Cure SMA and Cytokinetics Announce National Platinum Partnership for 2018
Cure SMA and Cytokinetics are very pleased to announce that Cytokinetics has committed to a National Platinum Partnership for 2018. Cytokinetics will be supporting several of Cure SMA’s awareness, education, and fundraising initiatives for spinal muscular atrophy (SMA), at both the local and national level.
As part of their partnership, Cytokinetics is sponsoring the 2018 Annual SMA Conference as a Visionary Sponsor, increasing their level of support for this unique event which brings together families affected by SMA, along with researchers and clinicians, to network, learn, and collaborate. If all goes as planned, Cytokinetics will soon begin a Phase III registration trial for their drug Reldesemtiv that targets muscle function. They will be sharing results from their Phase II trial and plans for their Phase III trial at the Conference.
Cytokinetics is also a member of the Cure SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit organizations, to share information, ideas, and data. The SMA Industry Collaboration works together to address scientific, clinical and regulatory topics that are critical to advancing drug development in SMA and will benefit the broader SMA community.
In addition, Cytokinetics will both sponsor and participate in two local events, the Concert for a Cure and the Northern California Walk-n-Roll. These are two of the largest fundraisers in Cytokinetics’ home base of Northern California, raising a combined $263,000 in 2017, and drawing nearly 700 participants from the community.
Finally, Cytokinetics will sponsor the 2018 “Hope on the Hill” Congressional Dinner. This annual event unites families with leaders from government and industry, to work on shared goals like increasing awareness, advancing treatments for SMA, and improving patient care.
“Cytokinetics has become one of our community’s most valued partners, and we are excited to have them back for another year of partnership” said Kenneth Hobby, president of Cure SMA. Because CK-2127107 targets the muscles directly, it is an important program for our goal of attacking SMA through multiple avenues, in order to gain approved treatments for all ages, types, and stages of SMA. We thank them for their dedication to our community and look forward to another productive year together.”
Through collaboration with our partners, like Cytokinetics, Cure SMA is working toward a world without SMA. On behalf of the entire community, we thank Cytokinetics for their ongoing partnership